Medtech 2025: Deregulation, Tariffs Anticipated From New US Administration

 
• By Natasha Barrow, Brian Bossetta, Elizabeth Orr, and Marion Webb

The incoming second Trump administration promises changes for medtech that include both the potential benefits of deregulation and the risks of tariffs. See what a dozen-plus industry experts had to say.

Medtech 2025 Administration
(Shutterstock)

More from Medtech Insight

More from Leadership